| Unique ID issued by UMIN | UMIN000017769 |
|---|---|
| Receipt number | R000020583 |
| Scientific Title | Ezetimibe lipid lowering trial on cholesterol absorption-synthesis and prevention of atherrosclerosis in 75 or older with hight risk hyper LDL cholesterolemia |
| Date of disclosure of the study information | 2015/06/02 |
| Last modified on | 2015/06/02 11:14:54 |
Ezetimibe lipid lowering trial on cholesterol absorption-synthesis and prevention of atherrosclerosis in 75 or older with hight risk hyper LDL cholesterolemia
KEEP(Kyushu Elderly Ezetimibe Phytosterol study)
Ezetimibe lipid lowering trial on cholesterol absorption-synthesis and prevention of atherrosclerosis in 75 or older with hight risk hyper LDL cholesterolemia
KEEP(Kyushu Elderly Ezetimibe Phytosterol study)
| Japan |
Hyper-LDL-cholesterolemia
| Medicine in general | Hepato-biliary-pancreatic medicine | Cardiology |
| Endocrinology and Metabolism | Neurology | Geriatrics |
Others
NO
To investigate the effects of ezetimibe on cholesterol absorption-synthesis and inflammation markers and cardiovascular events.
Efficacy
Confirmatory
Pragmatic
Not applicable
0 to 24weeks
(1)changes in cholesterol absorption and synthesis
(2)changes in inflammation markers
(3)changes in lipoproteins(RLPcholesterol, small dense LDL etc),
oxydised phospholipid, oxdised cholesterol)
(4)NT-proBNP
relation to composite
cardiovascular events(same as EWTOPIA75)
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Treatment
| Medicine |
ezetimibe and diet
diet
| 75 | years-old | <= |
| Not applicable |
Male and Female
(1) High-risk outpatients with hyper-LDL-cholesterolemia (serum LDL-cholesterol levels 140mg/dL) aged 75 years and older (at the time of written informed consent) of the both sexes (LDL-cholesterol levels are calculated with Friedewald Formula).
(2) At least one of the following factors
1. DM
2. Hypertension
3. Low-HDL-cholesterolemia
4. Hypertriglyceridemia
5. Current smoking
6. History of cerebral infarction
7. PAD
(1)Serum TG level400 mg/dL
(2) History of myocardial infarction
(3) History of PCI or CABG
(4) Angina pectoris requiring treatment
(5) Recent history of stroke(within 6 months)
(6) 1. AST100 IU/L 2. ALT100 IU/L 3. liver chirosis
(7) Serum creatinine level3.0 mg/dL
(8) Cancer
(9) Dementia
(10) Familial hyperchoresterolemia
(11) Atrial fibrillation
(12) Allergy to ezetimibe
(13) Patients participating in other clinical trials
(14) Patients inappropriate for the trial judged by investigators
1300
| 1st name | |
| Middle name | |
| Last name | Jun Sasaki,MD,PhD |
International University of Health and Welfare
Department of medical treatment for health
2-4-16 Momochihama Sawaraku,Fukuoka,Japan
092-407-0434
fukuoka-shiken@iuhw.ac.jp
| 1st name | |
| Middle name | |
| Last name | Jun Sasaki,MD,PhD |
International University of Health and Welfare
Department of medical treatment for health
2-4-16 Momochihama Sawaraku,Fukuoka,Japan
092-407-0434
fukuoka-shiken@iuhw.ac.jp
International University of Health and Welfare
International University of Health and Welfare
Other
Japan
NO
国際医療福祉大学
| 2015 | Year | 06 | Month | 02 | Day |
Unpublished
No longer recruiting
| 2015 | Year | 03 | Month | 24 | Day |
| 2015 | Year | 04 | Month | 01 | Day |
| 2017 | Year | 12 | Month | 31 | Day |
| 2015 | Year | 06 | Month | 02 | Day |
| 2015 | Year | 06 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020583